Lyophilised antigen composition
AssigneeGlaxosmithkline Biologicals SA
InventorDominique Ingrid Lemoine
Life of this patent
Estimating the term…
Abstract
The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided.
Claims20
A method of making a lyophilised composition for use in a reconstitution solution said method comprising the steps of:
- mixing WT-1 antigen having an isoelectric point which is lower than the pH of the reconstitution solution and TLR9 agonist, and submitting the resulting formulation to a lyophilisaton cycle.
A method of making a composition comprising a WT-1 antigen and a TLR9 agonist, said method comprising the steps of:
- mixing WT-1-A10 antigen having an isoelectric point between 5.858 and 7.5 and a CpG-containing immunostimulatory oligonucleotide selected from the group consisting of:
- SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 and SEQ ID NO 5, and submitting the resulting formulation to a lyophilisaton cycle.
A method of making an immunogenic composition for use in a reconstituting solution comprising the steps of:
- mixing WT-1 antigen and CpG-containing immunostimulatory oligonucleotide TLR9 agonist,
- submitting the resulting formulation to a lyophilisaton cycle, and
- reconstituting the lyophilised composition in a reconstitution solution having a pH which is higher than the isoelectric point of the WT-1 antigen.
Dependencies are inferred from the claim text.